A randomized, double-blind, placebo-controlled, risperidone-referenced, parallel-group, adaptive-design study of the efficacy, safety, and tolerability of vabicaserin (SCA-136) in subjects with acute exacerbations of schizophrenia

Trial Profile

A randomized, double-blind, placebo-controlled, risperidone-referenced, parallel-group, adaptive-design study of the efficacy, safety, and tolerability of vabicaserin (SCA-136) in subjects with acute exacerbations of schizophrenia

Completed
Phase of Trial: Phase II

Latest Information Update: 19 Mar 2014

At a glance

  • Drugs Vabicaserin (Primary) ; Risperidone
  • Indications Schizophrenia
  • Focus Therapeutic Use
  • Most Recent Events

    • 08 Jun 2012 Actual patient number 199 added as reported by ClinicalTrials.gov.
    • 08 Jun 2012 Actual end date Jun 2008 added as reported by ClinicalTrials.gov
    • 22 Jun 2008 Status changed from initiated to discontinued as reported by ClinicalTrials.gov.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top